Shots:

• Ujvira is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) utilizing a stable linker by Antibody Drug Conjugation and is supported by drug development program
• Ujvira be available in 2 strengths (100 & 60mg) and the therapy will be priced at nearly 80% less than the currently available option in the market (Rs. 1-59-225 for 100 mg vial)
• Patients already treated with Trastuzumab may still suffer with the disease and would require this therapy as the next step. The expensiveness is a barrier to availing this therapy and Ujvira will resolve this need

Ref: Zydus Cadila | Image: Dalal Street Investment Journa